Furthermore, AXL can mediate the resistance of head and neck cancer to cetuximab through two mechanisms: (1) Activation of HER3 via up-regulation of HER3 ligand neuromodulator 1 (NRG1) [103]; and (2) Activation of c-ABL kinase via Tyr821 of AXL [104]. The gene discussed is AXL; the disease is head and neck cancer.